Dihydroergotamine mesilate inhalation - Allergan

Drug Profile

Dihydroergotamine mesilate inhalation - Allergan

Alternative Names: DHE-inhalation - MAP; Levadex®; MAP 0004; SEMPRANA

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MAP Pharmaceuticals
  • Developer Allergan
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Preregistration Migraine

Most Recent Events

  • 22 Feb 2016 Allergan announces intention to submit NDA to US FDA in 2016
  • 29 Jun 2015 Dihydroergotamine mesilate inhalation is still in Preregistration for Migraine (in adults) in USA
  • 31 Mar 2015 Dihydroergotamine mesilate inhalation is still in clinical development for Migraine (in adolescents)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top